Study guide

6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation

UEMS European Board of Dermatovenereology Diploma Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Eligibility & Examination Regulations

1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition

2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology

2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns

3 Chapter 3: Dermatopathology & Diagnostic Procedures

3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy

4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology

4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance

5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease

5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders

6 Chapter 6: Hair, Nails & Pigmentary Disorders

6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation

7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease

7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses

8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease

8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease

9 Chapter 9: Autoimmune Bullous Diseases

9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis

10 Chapter 10: Eczematous Disorders, Urticaria & Allergology

10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy

11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis

11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses

12 Chapter 12: Paediatric & Genetic Dermatology

12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa

13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections

13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections

14 Chapter 14: Viral & Fungal Cutaneous Infections

14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses

15 Chapter 15: Sexually Transmitted Infections & Genital Infections

15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis

16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine

16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems

17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours

17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases

18 Chapter 18: Melanocytic Naevi & Melanoma

18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma

19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas

19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas

20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing

20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy

21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures

21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy

22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision

22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review

6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation

Key Takeaways Explain This Topic AI

Vitiligo affects about 0.5% to 1% of people worldwide; non-segmental vitiligo is symmetric and autoimmune, while segmental vitiligo is unilateral, starts early, and stabilises quickly.

Ruxolitinib 1.5% cream is approved in the EU for non-segmental vitiligo with facial involvement in patients aged 12 years and older.

Stable segmental vitiligo that does not respond to medical treatment is the best indication for surgical grafting, such as melanocyte-keratinocyte transplantation.

Melasma treatment rests on strict photoprotection, including tinted sunscreens against visible light, plus topical agents such as hydroquinone triple-combination cream or azelaic acid.

Peutz-Jeghers syndrome, caused by STK11 mutations, combines lip and oral mucosal lentigines with gastrointestinal hamartomatous polyps and a raised cancer risk.

Last updated: September 2026

6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation

Skin colour depends mainly on melanin , made by melanocytes in the basal layer and transferred in melanosomes to keratinocytes. Tyrosinase is the key enzyme. Eumelanin is brown-black, and pheomelanin is red-yellow; the balance depends partly on the MC1R receptor. Differences between skin types reflect melanosome size, number, and distribution, not melanocyte number.

A Wood lamp (UVA around 365 nm) helps separate epidermal from dermal pigment. Epidermal hyperpigmentation looks darker under Wood light, and depigmentation (vitiligo) shows as bright chalky white.

Vitiligo

Vitiligo is an acquired loss of melanocytes causing well-defined depigmented (milk-white) macules. Prevalence is about 0.5–1% .

Classification

Type Features Course

Non-segmental (NSV) Symmetric macules on the face (periorificial), hands, wrists, genitals, and bony sites; generalised, acrofacial, or universal forms; Koebner phenomenon Chronic and unpredictable; linked to autoimmune thyroid disease and other autoimmunity

Segmental (SV) Unilateral band-like patch, often starting in childhood; early leukotrichia (white hairs) Spreads quickly then stabilises within about 1–2 years ; responds poorly to medical therapy

Mixed Segmental vitiligo followed by non-segmental lesions —

Pathogenesis of NSV: melanocyte stress and an autoimmune attack by CD8+ T cells , driven by interferon-gamma and the CXCL10/JAK-STAT pathway . This explains the effect of JAK inhibitors.

Signs of activity: confetti-like depigmentation, trichrome lesions (an intermediate zone of partial pigment loss), inflammatory borders, and Koebner phenomenon. Activity and extent can be tracked with tools such as the VASI (Vitiligo Area Scoring Index).

Work-up: thyroid function and thyroid antibodies, and other tests only if symptoms suggest them.

European Treatment Approach

Goal Options

Stop active spread Oral mini-pulse corticosteroids (for example dexamethasone on 2 days a week) for rapidly progressing disease; phototherapy

Repigment limited disease Topical corticosteroids (body) or topical calcineurin inhibitors (face, flexures); ruxolitinib 1.5% cream (EU-approved for non-segmental vitiligo with facial involvement from 12 years)

Repigment extensive disease Narrowband UVB 2–3 times a week, often combined with topical agents; response is best on the face and poor on hands and feet

Stable, refractory patches Surgery once disease is stable for at least about 12 months: punch grafts, suction blister grafts, or melanocyte-keratinocyte transplantation ; best for segmental vitiligo

  • Extensive (over about 80%) refractory disease Depigmentation of remaining pigment in selected patients
  • All patients Sun protection, cosmetic camouflage, and psychological support

Repigmentation usually starts perifollicularly , because the hair follicle holds a reservoir of melanocytes. Areas without hair (lips, fingertips) respond poorly.

Other Causes of Hypopigmentation

  • Condition Clues
  • Piebaldism Congenital, stable, white forelock and ventral white patches; KIT mutation
  • Waardenburg syndrome White forelock, heterochromia of the irises, deafness
  • Tuberous sclerosis Ash-leaf macules, confetti macules (see genodermatoses)

Oculocutaneous albinism Generalised hypopigmentation from birth, nystagmus, reduced vision; high skin cancer risk; OCA1 is caused by TYR mutations

Pityriasis versicolor Fine scaly hypo- or hyperpigmented macules on the upper trunk; Malassezia ; KOH shows "spaghetti and meatballs"; treat with ketoconazole shampoo or azoles

Pityriasis alba Ill-defined pale scaly patches on the faces of atopic children

Idiopathic guttate hypomelanosis Small porcelain-white macules on sun-exposed shins and forearms of older adults

Progressive macular hypomelanosis Symmetrical pale macules on the trunk of young adults; red follicular fluorescence ( Cutibacterium acnes )

Post-inflammatory hypopigmentation After eczema, psoriasis, cryotherapy, or steroid injection

Leprosy and hypopigmented mycosis fungoides Leprosy patches lose sensation; consider MF in darker-skinned young people with persistent patches

  • Naevus depigmentosus Stable, congenital, well-defined off-white patch
  • Hyperpigmentation
  • Melasma

Who: mainly women with skin types III–V; triggered by UV and visible light , pregnancy (chloasma), hormonal contraception, and genetics.

Clinical: symmetric light-to-dark brown patches on the forehead, cheeks, upper lip, and chin (centrofacial and malar patterns).

Depth: epidermal, dermal, or mixed. Wood lamp and dermoscopy help, and dermal pigment responds less well.

Treatment:

Strict photoprotection with broad-spectrum sunscreen that also protects against visible light , using tinted products with iron oxides.

Hydroquinone 2–4% (prescription-only in the EU; banned from cosmetics) or triple-combination cream (hydroquinone + tretinoin + fluocinolone acetonide) for limited periods.

Azelaic acid , tranexamic acid (topical or oral, off-label; exclude thrombotic risk), and chemical peels.

Lasers and intense pulsed light only with caution, because they can cause rebound pigmentation .

Prolonged hydroquinone use can cause exogenous ochronosis (blue-black pigmentation).

Post-Inflammatory Hyperpigmentation (PIH)

PIH follows acne, eczema, lichen planus, trauma, or procedures, and is most marked in darker skin types. Treat the underlying inflammation early, protect from sun, and use azelaic acid, retinoids, or hydroquinone if needed.

Drug-Induced and Systemic Hyperpigmentation

Cause Pattern

Minocycline Blue-black in scars (type I), on normal shins and forearms (type II), or diffuse muddy-brown on sun-exposed skin (type III)

  • Amiodarone Slate-grey or violaceous pigmentation of sun-exposed skin; also photosensitivity
  • Antimalarials Blue-grey pigmentation of the shins, face, hard palate, and nails
  • Chemotherapy Bleomycin : flagellate streaks; 5-fluorouracil : serpentine pigmentation over veins
  • Clofazimine Red-brown skin discolouration
  • Addison disease Diffuse bronze pigment, darker in palmar creases, scars, and mucosa
  • Haemochromatosis Bronze or grey skin with liver disease and diabetes
  • Argyria Blue-grey skin after silver exposure
  • Lentigines and Lentiginous Syndromes

Solar lentigines: in chronically sun-exposed skin. PUVA lentigines follow photochemotherapy. Ephelides (freckles) darken in summer.

Peutz-Jeghers syndrome ( STK11 ): lentigines of the lips, buccal mucosa , fingers, and toes; hamartomatous GI polyps (intussusception, bleeding); increased GI, breast, pancreatic, and other cancer risk.

Laugier-Hunziker syndrome: acquired oral and lip lentigines with longitudinal melanonychia, without systemic disease.

Noonan syndrome with multiple lentigines (formerly LEOPARD, PTPN11 ) and Carney complex ( PRKAR1A : lentigines, cardiac myxomas, endocrine tumours).

Café-au-lait macules: six or more (over 5 mm before puberty, over 15 mm after) suggest NF1 .

Becker naevus: a unilateral brown patch with increased hair on the shoulder of adolescent boys.

Dermal Melanocytosis

Congenital dermal melanocytosis ("Mongolian spot"): blue-grey patches over the sacrum in infants with darker skin; fades in childhood.

Naevus of Ota: blue-grey pigment in the first and second divisions of the trigeminal nerve, with ocular melanocytosis . It carries a risk of glaucoma and, rarely, melanoma of the eye or skin. Q-switched or picosecond lasers are effective.

Naevus of Ito: the same over the shoulder (supraclavicular and lateral brachial nerves).